Skip to main content
SpringerLink
Log in

Einsatz von Bisphosphonaten zur Behandlung von primären und sekundären Osteopathien im Kindes- und Jugendalter

  • Chapter
Fortbildung Osteologie

Part of the book series: Fortbildung Osteologie ((FORTOSTEO,volume 3))

  • 1441 Accesses

Zusammenfassung

In der Erwachsenenmedizin liegen zahlreiche klinische Studien vor, die die Wirkung von Bisphosphonaten als effektive Hemmer der Knochenresorption eindeutig belegen [17], [19], [21], [35]. Bisphosphonate sind im Erwachsenenalter hauptsächlich zur Behandlung der Osteoporose oder der tumorassoziierten Hyperkalziämie indikationsabhängig zugelassen [18], [20], [21]. Der erfolgreiche Einsatz von Bisphosphonaten beim Morbus Paget des Erwachsenen ist durch langjährige Erfahrungen belegt [40]. Anhand des aktuellen Wissensstandes scheinen Bisphosphonate in der Mehrzahl aller Osteopathien therapeutisch hilfreich zu sein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. Alharbi M, Pinto G, Finidori G et al. (2008) Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res 71: 38–44

    Article  PubMed  Google Scholar 

  2. Auron A, Tal L, Srivastava T, Alon US (2009) Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates. Pediatr Nephrol: 24(3): 613–617, Epub 2008 Oct 7

    Article  PubMed  Google Scholar 

  3. Bachrach, L.K., Ward, L.M. (2009) Clinical Review: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94(2): 400–409

    Article  CAS  PubMed  Google Scholar 

  4. Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M (2008) Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 21: 811–818

    PubMed  Google Scholar 

  5. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M (2003) Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 39: 88–92

    Article  CAS  PubMed  Google Scholar 

  6. Body JJ, Bartl R, Burckhardt P et al. (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890–3899

    CAS  PubMed  Google Scholar 

  7. Cassinelli HR, Mautalen CA, Heinrich JJ, Miglietta A, Bergada C (1992) Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD). Bone Miner 19: 175–184

    Article  CAS  PubMed  Google Scholar 

  8. Castillo H, Samson-Fang L (2009) Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 51:17–29

    Article  PubMed  Google Scholar 

  9. Cecchini MG, Fleisch H (1990) Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5: 1019–1027

    Article  CAS  PubMed  Google Scholar 

  10. Chong B, Hedge M, Fawkner M et al. (2003) Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 18: 2095–2104

    Article  CAS  PubMed  Google Scholar 

  11. Ciana G, Cuttini M, Bembi B (1997) Short-term effects of pamidronate in patients with Gaucher’s disease and severe skeletal involvement. N Engl J Med 337: 712

    Article  CAS  PubMed  Google Scholar 

  12. Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153: 719–720

    Article  CAS  PubMed  Google Scholar 

  13. Cundy T, Hegde M, Naot D et al. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11: 2119–2127

    Article  CAS  PubMed  Google Scholar 

  14. Demir E, Bereket A, Ozkan B, Topcu M (2000) Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab 13 217–221

    CAS  PubMed  Google Scholar 

  15. Evequoz V, Trechsel U, Fleisch H (1985) Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes. Bone 6: 439–444

    Article  CAS  PubMed  Google Scholar 

  16. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111: 573–578

    Article  PubMed  Google Scholar 

  17. Fleisch H (1989) Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 116: 1–28

    CAS  PubMed  Google Scholar 

  18. Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919–944

    Article  CAS  PubMed  Google Scholar 

  19. Fleisch H (1997) Mechanisms of action of the bisphosphonates. Medicina (B Aires) 57, Suppl 1: 65–75

    CAS  Google Scholar 

  20. Fleisch H (2001) Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease. Semin Oncol 28: 45–47

    Article  CAS  PubMed  Google Scholar 

  21. Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4: 30–34

    Article  CAS  PubMed  Google Scholar 

  22. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A (1998) Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 157: 261–262

    CAS  PubMed  Google Scholar 

  23. Glorieux FH (2001) The use of bisphosphonates in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab: 14, Suppl 6: 1491–1495

    PubMed  Google Scholar 

  24. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947–952

    Article  CAS  PubMed  Google Scholar 

  25. Gong L, Hoshi K, Ejiri S, Nakajima T, Shingaki S, Ozawa H (2003) Bisphosphonate incadronate inhibits maturation of ectopic bone induced by recombinant human bone morphogenetic protein 2. J Bone Miner Metab 21: 5–11

    Article  CAS  PubMed  Google Scholar 

  26. Levy S, Fayez I, Taguchi N et al. (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44(3): 428–430

    Article  CAS  PubMed  Google Scholar 

  27. Marini JC (2003) Do bisphosphonates make children’s bones better or brittle? N Engl J Med 349: 423–426

    Article  PubMed  Google Scholar 

  28. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, Glorieux FH (2003) Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 111: 601–603

    Article  Google Scholar 

  29. Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 4, CD005088

    PubMed  Google Scholar 

  30. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 1846–1850

    Article  CAS  PubMed  Google Scholar 

  31. Rauch F, Glorieux FH (2000) Bisphosphonate in der Pädiatrie. Monschr Kdheilkd 148: 334–341

    Google Scholar 

  32. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88: 986–992

    Article  CAS  PubMed  Google Scholar 

  33. Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 1293–1299

    CAS  PubMed  Google Scholar 

  34. Robinson C, Baker N, Noble J et al. (2002) The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J Inherit Metab Dis 25: 681–693

    Article  CAS  PubMed  Google Scholar 

  35. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692–2696

    Article  CAS  PubMed  Google Scholar 

  36. Roth AJ, Abendroth K, Seidel J, Neubert H, Venbrocks R (1996) Management of primary idiopathic hyperphosphatasemia with calcitonin: a case report. Int Orthop 20: 58–60

    Article  CAS  PubMed  Google Scholar 

  37. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA (1994) Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher’s disease. Pediatrics 94: 385–389

    CAS  PubMed  Google Scholar 

  38. Schoenau E, Rauch F (2002) Fibrous dysplasia. Horm Res 57, Suppl2: 79–82

    Article  CAS  PubMed  Google Scholar 

  39. Seidel J, Abendroth K, Müller A, Kauf E (1998) Hyperostosis corticalis deformans juvenilis/HCDJ-Ergebnisse nach 2,5 jähriger Pamidronat-Therapie. Osteologie 7 (Suppl 1): 69

    Google Scholar 

  40. Singer FR, Clemens TL, Eusebio RA, Bekker PJ (1998) Risedronate, a highly effective oral agent in the treatment of patients with severe Pagets disease. J Clin Endocrinol Metab 83: 1906–1910

    Article  CAS  PubMed  Google Scholar 

  41. Singer F, Siris E, Shane E, Dempster D, Lindsay R, Parisien M (1994) Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. J Bone Miner Res 9: 733–738

    Article  CAS  PubMed  Google Scholar 

  42. Singer FR, Minoofar PN (1995) Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 6 259–288

    CAS  PubMed  Google Scholar 

  43. Srivastava T, Alon US (2003) The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162: 735–751

    Article  CAS  PubMed  Google Scholar 

  44. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680–686

    Article  CAS  PubMed  Google Scholar 

  45. Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324–2333

    Article  CAS  PubMed  Google Scholar 

  46. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457–463

    Article  CAS  PubMed  Google Scholar 

  47. Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111: 1030–1036

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kinderendokrinologe,-diabetologe Klinik für Kinder- und Jugendmedizin, SRH-Wald-Klinikum Gera GmbH, Straße des Friedens 122, D-07548, Gera

    Prof. Dr. med. habil. Jörg Seidel

Authors
  1. Prof. Dr. med. habil. Jörg Seidel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Seidel, J. (2010). Einsatz von Bisphosphonaten zur Behandlung von primären und sekundären Osteopathien im Kindes- und Jugendalter. In: Fortbildung Osteologie. Fortbildung Osteologie, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05385-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-05385-6_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05384-9

  • Online ISBN: 978-3-642-05385-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation